J
John S. March
Researcher at Duke University
Publications - 28
Citations - 9330
John S. March is an academic researcher from Duke University. The author has contributed to research in topics: Anxiety & Cognitive behavioral therapy. The author has an hindex of 25, co-authored 28 publications receiving 8637 citations. Previous affiliations of John S. March include University of Chicago & Pfizer.
Papers
More filters
Journal ArticleDOI
The Multidimensional Anxiety Scale for Children (MASC): Factor Structure, Reliability, and Validity
TL;DR: The MASC factor structure, which presumably reflects the in the vivo structure of pediatric anxiety symptoms, is invariant across gender and age and shows excellent internal reliability and is a promising self-report scale for assessing anxiety in children and adolescents.
Journal ArticleDOI
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
John S. March,Susan G. Silva,Stephen Petrycki,John F. Curry,Karen C. Wells,John A. Fairbank,Barbara J. Burns,Marisa Elena Domino,Steven McNulty,Benedetto Vitiello,Joanne B. Severe +10 more
TL;DR: The combination of fluoxetine with CBT offered the most favorable tradeoff between benefit and risk for adolescents with major depressive disorder.
Journal ArticleDOI
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
John T. Walkup,Anne Marie Albano,John Piacentini,Boris Birmaher,Scott N. Compton,Joel Sherrill,Golda S. Ginsburg,Moira A. Rynn,James T. McCracken,Bruce Waslick,Satish Iyengar,John S. March,Philip C. Kendall +12 more
TL;DR: Both cognitive behavioral therapy and sertraline reduced the severity of anxiety in children with anxiety disorders; a combination of the two therapies had a superior response rate.
Journal ArticleDOI
Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The pediatric OCD treatment study (POTS) randomized controlled trial
Journal ArticleDOI
The Treatment for Adolescents with Depression Study (TADS): Long-term effectiveness and safety outcomes
John S. March,Susan G. Silva,Stephen Petrycki,John F. Curry,Karen C. Wells,John A. Fairbank,Barbara J. Burns,Marisa Elena Domino,Steven McNulty,Benedetto Vitiello,Joanne B. Severe,Charles D. Casat,Jeanette Kolker,Karyn Riedal,Norah C. Feeny,Robert L. Findling,Sheridan Stull,Susan Baab,Elizabeth B. Weller,Michele Robins,Ronald A. Weller,Naushad Jessani,Bruce Waslick,Michael Sweeney,Randi Dublin,John T. Walkup,Golda S. Ginsburg,Elizabeth Kastelic,Hyung Koo,Christopher J. Kratochvil,Diane May,Randy LaGrone,Brigette Vaughan,Anne Marie Albano,Glenn S. Hirsch,Elizabeth Podniesinki,Mark A. Reinecke,Mark A. Reinecke,Bennett L. Leventhal,Bennett L. Leventhal,Gregory M. Rogers,Gregory M. Rogers,Rachel H. Jacobs,Rachel H. Jacobs,Sanjeev Pathak,Jennifer Wells,Sarah Arszman,Arman Danielyan,Paul Rohde,Anne D. Simons,James Grimm,Stephenie Frank,Graham J. Emslie,Beth D. Kennard,Carroll W. Hughes,Taryn L. Mayes,David R. Rosenberg,Nili R. Benazon,Michael Butkus,Marla Bartoi,Kelly Posner,James Rochon +61 more
TL;DR: In adolescents with moderate to severe depression, treatment with fluoxetine alone or in combination with CBT accelerates the response and combined treatment appears superior to either monotherapy as a treatment for major depression in adolescents.